Innovative Ketamine News: Esketamine Approved by the FDA
As many of you have heard, there is a new treatment for depression: Esketamine. Recently, Johnson & Johnson, a pharmaceutical company, has manufactured a new medication called Spravato or Esketamine. This is a close chemical relation to ketamine, an anesthetic which has been used for 50 years. Johnson & Johnson will be getting FDA approval which specifically states that the drug will only be available in certified clinics where doctors can monitor the patient, which is a move to attempt to decrease the risk of abuse.
Here is what you need to know about as Esketamine:
Esketamine spray is the first novel medication to be approved by the FDA to treat depression since Prozac, which came to the market in 1988.
Innovative Ketamine, is clinic located near Wrigleyville in Chicago, Illinois and has already been using generic nasal Ketamine for the last year. The clinic also uses intravenous (IV) ketamine for severe depression. The outcomes for IV ketamine are superior that the nasal spray, however having FDA approval of a medication that is almost identical to Ketamine is a significant step in the right direction.
If you or anyone you love is suffering from depression, please let them know there is a new treatment. We have had a 70-75% success rate in treating treatment-resistant depression.
On a personal note, I have not seen a treatment like Ketamine in my lifetime. The amount of people we have treated at Innovative Ketamine who have turned their life around is staggering. I encourage you to make an appointment and discuss your symptoms with us.